^
    HIF1A overexpression
    HER2 Negative Breast Cancer
    albumin-bound paclitaxel
    Sensitive
    :
    B
    ESMO-BC 2021 - 1wk
    BACH1 overexpression
    HER2 Negative Breast Cancer
    albumin-bound paclitaxel
    Sensitive
    :
    B
    ESMO-BC 2021 - 1wk
    HR positive
    HER2 Negative Breast Cancer
    ribociclib
    Sensitive
    :
    A1
    ESMO-BC 2021 - 1wk
    PIK3CA mutation + HR positive
    HER2 Negative Breast Cancer
    alpelisib
    Sensitive
    :
    A1
    The Oncologist - 1wk
    HR positive
    HER2 Negative Breast Cancer
    abemaciclib
    Sensitive
    :
    A1
    ESMO-BC 2021 - 1wk
    HER-2 negative
    HER2 Negative Breast Cancer
    bevacizumab
    Sensitive
    :
    A2
    ESMO-BC 2021 - 1wk
    ER positive
    HER2 Negative Breast Cancer
    palbociclib
    Sensitive
    :
    B
    ESMO-BC 2021 - 1wk
    ER positive
    HER2 Negative Breast Cancer
    letrozole
    Sensitive
    :
    C2
    ESMO-BC 2021 - 1wk
    ER positive
    HER2 Negative Breast Cancer
    ribociclib
    Sensitive
    :
    C2
    ESMO-BC 2021 - 1wk
    HR positive
    HER2 Negative Breast Cancer
    eribulin mesylate
    Sensitive
    :
    C2
    ESMO-BC 2021 - 1wk
    ER positive + PGR positive
    HER2 Negative Breast Cancer
    tamoxifen
    Sensitive
    :
    C3
    ESMO-BC 2021 - 1wk
    HR positive
    HER2 Negative Breast Cancer
    palbociclib
    Sensitive
    :
    A1
    Cancer Invest - 2wk
    HER-2 negative
    HER2 Negative Breast Cancer
    eribulin mesylate
    Sensitive
    :
    A2
    Int J Clin Oncol - 2wk
    HR positive
    HER2 Negative Breast Cancer
    everolimus
    Sensitive
    :
    A1
    BRCA2 mutation
    HER2 Negative Breast Cancer
    talazoparib
    Sensitive
    :
    A1
    BRCA1 mutation
    HER2 Negative Breast Cancer
    talazoparib
    Sensitive
    :
    A1
    BRCA1 mutation
    HER2 Negative Breast Cancer
    olaparib
    Sensitive
    :
    A1
    BRCA2 mutation
    HER2 Negative Breast Cancer
    olaparib
    Sensitive
    :
    A1
    HR positive
    HER2 Negative Breast Cancer
    fulvestrant
    Sensitive
    :
    A1
    HER-2 negative
    HER2 Negative Breast Cancer
    CaT
    Sensitive
    :
    A2
    HER-2 negative
    HER2 Negative Breast Cancer
    ribociclib
    Sensitive
    :
    A2
    HER-2 negative
    HER2 Negative Breast Cancer
    docetaxel
    Sensitive
    :
    A2
    HER-2 negative
    HER2 Negative Breast Cancer
    paclitaxel
    Sensitive
    :
    A2
    HER-2 negative
    HER2 Negative Breast Cancer
    albumin-bound paclitaxel
    Sensitive
    :
    A2
    HER-2 negative
    HER2 Negative Breast Cancer
    ixabepilone
    Sensitive
    :
    A2
    HER-2 negative
    HER2 Negative Breast Cancer
    capecitabine
    Sensitive
    :
    A2
    HER-2 negative
    HER2 Negative Breast Cancer
    gemcitabine
    Sensitive
    :
    A2
    HER-2 negative
    HER2 Negative Breast Cancer
    vinorelbine tartrate
    Sensitive
    :
    A2
    HR positive
    HER2 Negative Breast Cancer
    toremifene
    Sensitive
    :
    A2
    HER-2 negative
    HER2 Negative Breast Cancer
    letrozole
    Sensitive
    :
    A2
    HER-2 negative
    HER2 Negative Breast Cancer
    anastrozole
    Sensitive
    :
    A2
    HER-2 negative
    HER2 Negative Breast Cancer
    carboplatin + docetaxel
    Sensitive
    :
    A2
    HER-2 negative
    HER2 Negative Breast Cancer
    tamoxifen
    Sensitive
    :
    A2
    HER-2 negative
    HER2 Negative Breast Cancer
    carboplatin + albumin-bound paclitaxel
    Sensitive
    :
    A2
    HER-2 negative
    HER2 Negative Breast Cancer
    everolimus
    Sensitive
    :
    A2
    HER-2 negative
    HER2 Negative Breast Cancer
    TC
    Sensitive
    :
    A2
    HER-2 negative
    HER2 Negative Breast Cancer
    fulvestrant
    Sensitive
    :
    A2
    VERI is free for non-commercial use, no login needed.
    Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
    For commercial access, including additional premium features, please contact us.
    By using VERI, you are agreeing to our
    and
    Privacy Policy
    ACCEPT COOKIES